Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

  • STATUS
    Recruiting
  • days left to enroll
    4
  • participants needed
    252
  • sponsor
    ImmunoGen, Inc.
Updated on 3 May 2022
cancer
blast crisis
flow cytometry
chronic myelomonocytic leukemia
leukemia
refractory acute myeloid leukemia (aml)
acute promyelocytic leukemia
blast cells

Summary

This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease.

The study is enrolling a pivotal cohort of frontline BPDCN patients and a cohort of relapsed/refractory BPDCN patients.

Description

The study completed a dose escalation phase, and is now enrolling in a dose expansion phase to further characterize the safety profile and to assess the efficacy of IMGN632 in patients with BPDCN. IMGN632 is administered by IV on Day 1 of each cycle, with cycles repeating every 21 days.

Details
Condition Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myeloproliferative Neoplasm
Treatment IMGN632
Clinical Study IdentifierNCT03386513
SponsorImmunoGen, Inc.
Last Modified on3 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Disease Characteristics
Confirmation of CD123 positivity by flow cytometry or IHC. Patients who received prior CD123-targeting agents will be allowed as long as the blasts still have detectable CD123 expression
Expansion inclusion
Cohort 1 - Patients with relapsed or refractory BPDCN with 1-3 prior lines of therapy
Cohort 2 - Patients will have relapsed AML
Cohort 3 - Patients will have relapsed or refractory ALL (including any subtypes: B-cell, T-cell, Ph+, and Ph-)
Cohort 4 - Patients will have relapsed or refractory "other" hematologic malignancies not included in the cohorts above (eg, high-risk/very high-risk MDS, MPN, CMML, BP- CML). Other CD123+ malignancies may be considered upon discussion with the Sponsor
Cohort 5 - Patients will have relapsed or refractory (to non-intense therapies) AML
Cohort 6 - Patients with frontline BPDCN who have not received prior systemic therapy
Note: Patients in Cohort 6 may have received local therapy (radiotherapy, surgical
excision, photodynamic therapy). Eligible patients must have a recurrence or progression in
the field of local therapy OR disease outside the field of local therapy

Exclusion Criteria

Patients who, in the judgment of their treating physician, have appropriate standard
of care therapies will be excluded from Cohorts 1 through 5
Frontline BPDCN patients with central nervous system (CNS) disease will be excluded. A
Patients with a history of veno-occlusive disease of the liver
lumbar puncture must be performed during the 28-day screening period, prior to drug
administration. Relapsed or refractory BPDCN patients with a known history of CNS
disease must have been treated locally, have at least 1 lumbar puncture with no
evidence of CNS disease, and must be clinically stable prior to first dose. Concurrent
therapy for CNS prophylaxis or continuation of therapy for controlled CNS disease is
permitted with the approval of the Sponsor
Patients with a history of Grade 4 capillary leak syndrome, or non-cardiac Grade 4
edema are ineligible, eg, related to tagraxofusp-erzs or other etiology
Interval from prior cancer therapy: 1. For frontline BPDCN patients with prior local
therapy (eg, radiotherapy), patients must not have received treatment within 14 days
prior to drug administration on this study. 2. Relapsed or refractory BPDCN patients
must not have received any anti-cancer therapy including chemotherapy, immunotherapy
radiotherapy, hormonal, biologic, or any investigational agents within 14 days prior
to drug administration on this study. Patients must have recovered to baseline from
all acute toxicity from this prior therapy
Note: the exception that patients who have received a checkpoint inhibitor must not have
received that therapy within 28 days prior to drug administration on this study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note